<DOC>
	<DOCNO>NCT00522821</DOCNO>
	<brief_summary>There consensus treatment patient recurrent infection isolate immunoglobulin G ( IgG ) -subclass deficiency and/or selective antipolysaccharide antibody deficiency . Therefore , Dutch Inter University Working Party start study treatment antibiotic compare intravenous immunoglobulin therapy respect clinical outcome measure child adult disorder .</brief_summary>
	<brief_title>Treatment Deficient Subclass Anti-polysaccharide Antibody Response</brief_title>
	<detailed_description>There consensus treatment patient recurrent infection isolate IgG-subclass deficiency and/or selective antipolysaccharide antibody deficiency . At present , robust criterion predict patient respond adequately antibiotic treatment IVIG . Furthermore , unknown whether IVIG treatment improve quality life patient . Therefore , Dutch InterUniversity Working Party intend start study patient group . In study , treatment year antibiotic compare year intravenous immunoglobulin therapy respect clinical outcome measure child adult disorder . The patient visit clinic every 3 month laboratory test physiological measurement perform . Moreover occurrence infection fever , use antibiotic , hospital admission , quality life document . The study result national harmonization treatment patient group . To end , result study used compile treatment protocol group patient Netherlands applicable also country worldwide .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>IgG subclass deficiency and/or ( selective ) antipolysaccharide antibody deficiency At least 2 physician document infection start current treatment last 6 month newly diagnose patient . Total serum IgG &gt; 4 g/l ≥ 5 year age Informed consent Treatment investigational drug within 7 day prior study entry , previous enrolment study Allergic reaction human plasma/plasma product , cotrimoxazole An ongoing progressive terminal disease Pregnancy lactation History ( transient ) cerebrovascular accident coronary insufficiency Renal insufficiency ( plasma creatinin &gt; 115 µmol/L ; creatinin clearance &lt; 20 ml/min ) An ongoing active disease cause general symptom e.g . chronic active hepatitis persistent enterovirus infection ongoing systemic complaint Detectable antiIgA antibody Active systemic lupus erythematosus ( SLE ) Glucose6phosphate hydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>IgG subclass deficiency</keyword>
	<keyword>Anti-polysaccharide deficiency</keyword>
	<keyword>therapy</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>co-trimoxazole</keyword>
</DOC>